We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

29 hedge funds and large institutions have $848K invested in MiNK Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.27% → 0.26% (-0.01%)

0% less capital invested

Capital invested by funds: $848K → $848K (-$278)

12% less funds holding

Funds holding: 33 → 29 (-4)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
29
Holders Change
-4
Holders Change %
-12.12%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$22K
2
BlackRock
BlackRock
New York
+$10.8K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.29K
4
Goldman Sachs
Goldman Sachs
New York
+$1.88K
5
Osaic Holdings
Osaic Holdings
Arizona
+$496

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1K
2
Citadel Advisors
Citadel Advisors
Florida
-$18.9K
3
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$18.1K
4
Millennium Management
Millennium Management
New York
-$6.79K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.05K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$222K – – –
LF
2
Longbow Finance
Switzerland
$158K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$121K +$22K +2,261 +21%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$91.5K +$7.29K +749 +8%
BlackRock
5
BlackRock
New York
$82.8K +$10.8K +1,105 +15%
HighTower Advisors
6
HighTower Advisors
Illinois
$43K -$185 -19 -0.4%
CAPTRUST Financial Advisors
7
CAPTRUST Financial Advisors
North Carolina
$33.9K -$18.1K -1,856 -34%
State Street
8
State Street
Massachusetts
$24.2K -$78 -8 -0.3%
Goldman Sachs
9
Goldman Sachs
New York
$16.7K +$1.88K +193 +12%
Millennium Management
10
Millennium Management
New York
$12.5K -$6.79K -698 -35%
Northern Trust
11
Northern Trust
Illinois
$10.5K -$29 -3 -0.3%
Wells Fargo
12
Wells Fargo
California
$10.3K -$156 -16 -1%
TRCT
13
Tower Research Capital (TRC)
New York
$8.49K -$2.05K -211 -19%
UBS Group
14
UBS Group
Switzerland
$3.06K -$10 -1 -0.3%
Bank of America
15
Bank of America
North Carolina
$1.93K -$1.07K -110 -35%
Qube Research & Technologies (QRT)
16
Qube Research & Technologies (QRT)
United Kingdom
$1.84K – – –
California State Teachers Retirement System (CalSTRS)
17
California State Teachers Retirement System (CalSTRS)
California
$1.47K – – –
Osaic Holdings
18
Osaic Holdings
Arizona
$1.36K +$496 +51 +55%
C
19
Covestor
United Kingdom
$1K – – –
Morgan Stanley
20
Morgan Stanley
New York
$363 -$214 -22 -37%
CCM
21
Chilton Capital Management
Texas
$294 – – –
CP
22
Camelot Portfolios
Ohio
$195 +$204 +21 New
Northwestern Mutual Wealth Management
23
Northwestern Mutual Wealth Management
Wisconsin
$181 – – –
GPFA
24
Game Plan Financial Advisors
Ohio
$161 – – –
CA
25
Clearstead Advisors
Ohio
$143 +$146 +15 New
1
2

INKT Hedge Fund Activity: Q2 2024 in Review

29 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q2 2024, worth a combined $848K — down 0.03% from $848K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of INKT and 2 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $22K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $27.1K sold.

  • 29 institutional investors held MiNK Therapeutics (INKT) as of Q2 2024, down from 33 in Q1 2024.
  • Funds reported $848K of MiNK Therapeutics stock for Q2 2024, down 0.03% quarter-over-quarter.
  • 2 funds opened new MiNK Therapeutics positions in Q2 2024 and 6 closed out, a net change of -4 holders.
  • The largest MiNK Therapeutics buyer in Q2 2024 was Renaissance Technologies, an estimated $22K added.
  • The largest MiNK Therapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $27.1K sold.

Based on aggregated 13F filings for Q2 2024.